1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Prostate cancer

Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer

Technology appraisal guidance [TA660] Published: 25 November 2020

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Tools and resources

Tools to help you put the guidance into practice.

Resource impact

  • Resource impact report PDF 239 KB 25 November 2020  
  • Resource impact template Excel 1.45 MB 25 November 2020  

Guidance into practice

  • About the Into practice guide  
  • Practical steps to improving the quality of care and services using NICE guidance